KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2025)

Ginkgo Bioworks Holdings' Non-Current Assets history spans 6 years, with the latest figure at $647.9 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 16.37% year-over-year to $647.9 million; the TTM value through Dec 2025 reached $2.8 billion, down 11.11%, while the annual FY2025 figure was $647.9 million, 16.37% down from the prior year.
  • Non-Current Assets reached $647.9 million in Q4 2025 per DNA's latest filing, down from $683.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.7 billion in Q1 2021 to a low of $340.0 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $798.6 million, with a median of $718.5 million recorded in 2025.
  • The largest YoY upside for Non-Current Assets was 213.05% in 2022 against a maximum downside of 79.6% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $347.9 million in 2021, then surged by 213.05% to $1.1 billion in 2022, then tumbled by 39.08% to $663.6 million in 2023, then rose by 16.74% to $774.7 million in 2024, then decreased by 16.37% to $647.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Non-Current Assets are $647.9 million (Q4 2025), $683.1 million (Q3 2025), and $708.0 million (Q2 2025).